BACKGROUND: Helper-dependent adenoviral vectors (HDAd) can mediate long-term phenotypic correction in the ornithine transacarbamylase (OTC)-deficient mice model with negligible chronic toxicity. However, the high doses required for metabolic correction will result in systemic inflammatory response syndrome in humans. This acute toxicity represents the major obstacle for clinical applications of HDAd vectors for the treatment of OTC deficiency. Strategies for reducing the dose necessary for disease correction are highly desirable because HDAd acute toxicity is clearly dose-dependent. METHODS: We analysed a potent expression cassette and the hydrodynamic injection for the ability to reduce the HDAd dose necessary for phenotypic correction in OTC-deficient spf-ash mice. RESULTS: We have developed a vector containing a potent expression cassette expressing the OTC transgene, which allowed phenotypic correction at lower doses. Our results suggest that vector expressing greater OTC levels allows correction of orotic acid overproduction at lower doses that make clinical translation more relevant. We were able to further reduce the minimal effective dose by delivering the vector through the hydrodynamic injection technique. CONCLUSIONS: Vectors containing the expression cassette used in the present study, combined with other strategies for improving HDAd therapeutic index, will likely permit application of these vectors for the treatment of OTC deficiency as well as other urea cycle disorders. (c) 2008 John Wiley & Sons, Ltd.
BACKGROUND: Helper-dependent adenoviral vectors (HDAd) can mediate long-term phenotypic correction in the ornithine transacarbamylase (OTC)-deficient mice model with negligible chronic toxicity. However, the high doses required for metabolic correction will result in systemic inflammatory response syndrome in humans. This acute toxicity represents the major obstacle for clinical applications of HDAd vectors for the treatment of OTC deficiency. Strategies for reducing the dose necessary for disease correction are highly desirable because HDAd acute toxicity is clearly dose-dependent. METHODS: We analysed a potent expression cassette and the hydrodynamic injection for the ability to reduce the HDAd dose necessary for phenotypic correction in OTC-deficient spf-ash mice. RESULTS: We have developed a vector containing a potent expression cassette expressing the OTC transgene, which allowed phenotypic correction at lower doses. Our results suggest that vector expressing greater OTC levels allows correction of orotic acid overproduction at lower doses that make clinical translation more relevant. We were able to further reduce the minimal effective dose by delivering the vector through the hydrodynamic injection technique. CONCLUSIONS: Vectors containing the expression cassette used in the present study, combined with other strategies for improving HDAd therapeutic index, will likely permit application of these vectors for the treatment of OTC deficiency as well as other urea cycle disorders. (c) 2008 John Wiley & Sons, Ltd.
Authors: Nicola Brunetti-Pierri; Donna J Palmer; Viraj Mane; Milton Finegold; Arthur L Beaudet; Philip Ng Journal: Mol Ther Date: 2005-07 Impact factor: 11.454
Authors: Nicola Brunetti-Pierri; Gary E Stapleton; Donna J Palmer; Yu Zuo; Viraj P Mane; Milton J Finegold; Arthur L Beaudet; Michelle M Leland; Charles E Mullins; Philip Ng Journal: Mol Ther Date: 2007-02-06 Impact factor: 11.454
Authors: Nicola Brunetti-Pierri; Timothy C Nichols; Stephanie McCorquodale; Elizabeth Merricks; Donna J Palmer; Arthur L Beaudet; Philip Ng Journal: Hum Gene Ther Date: 2005-07 Impact factor: 5.695
Authors: David Moscioni; Hiroki Morizono; Robert J McCarter; Adam Stern; Juan Cabrera-Luque; Albert Hoang; Julio Sanmiguel; Di Wu; Peter Bell; Guang-Ping Gao; Steven E Raper; James M Wilson; Mark L Batshaw Journal: Mol Ther Date: 2006-05-03 Impact factor: 11.454
Authors: P F Whitington; E M Alonso; J T Boyle; J P Molleston; P Rosenthal; J C Emond; J M Millis Journal: J Inherit Metab Dis Date: 1998 Impact factor: 4.982
Authors: Gregory M Enns; Susan A Berry; Gerard T Berry; William J Rhead; Saul W Brusilow; Ada Hamosh Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245
Authors: David Dimmock; Nicola Brunetti-Pierri; Donna J Palmer; Arthur L Beaudet; Philip Ng Journal: Hum Gene Ther Date: 2011-02-16 Impact factor: 5.695
Authors: Sharon C Cunningham; Afroditi Spinoulas; Kevin H Carpenter; Bridget Wilcken; Philip W Kuchel; Ian E Alexander Journal: Mol Ther Date: 2009-04-21 Impact factor: 11.454
Authors: Johannes Häberle; Nathalie Boddaert; Alberto Burlina; Anupam Chakrapani; Marjorie Dixon; Martina Huemer; Daniela Karall; Diego Martinelli; Pablo Sanjurjo Crespo; René Santer; Aude Servais; Vassili Valayannopoulos; Martin Lindner; Vicente Rubio; Carlo Dionisi-Vici Journal: Orphanet J Rare Dis Date: 2012-05-29 Impact factor: 4.123
Authors: Tristan R McKay; Ahad A Rahim; Suzanne M K Buckley; Natalie J Ward; Jerry K Y Chan; Steven J Howe; Simon N Waddington Journal: Curr Pharm Des Date: 2011 Impact factor: 3.116